BioWorld

Jan. 7, 2002

View Archived Issues

Abgenix Drops ABX-IL8 For RA Following Phase II Trial Results

Abgenix Inc. s stock took a small hit Friday following the disclosure that a Phase IIa study of its rheumatoid arthritis candidate failed to meet its endpoints. Read More

Aurora, Allergan Expand Work To Include GPCR Screening

Read More

Industry, Academia Knock Out Immune Rejection Gene From Porcine Xenotransplant Grafts

Read More

Acadia Partners With Amgen To Discover Small-Molecule Drugs

Read More

Other News To Note

Read More

3-D Pharma, J&J Collaborate On Small-Molecule Drug Discovery

Read More

Appointments And Advancements

Read More